OBJECTIVE: To determine the effect of low-dose cyclosporin A (CSA) treatment on disease activity in systemic lupus erythematosus (SLE). METHODS: All patients in the study had active disease as defined by at least the presence of a low CH50 level. Patients were initially given 3 mg/kg/day of CSA. Dosages were adjusted individually at every visit, according to both clinical and laboratory data. RESULTS: Eleven women with SLE were enrolled in the study; 10 were evaluable. After 20 weeks of CSA treatment, the mean score for disease activity on the SLE Disease Activity Index decreased significantly, from 10.6 to 3.8 (P = 0.02). The titer of antinuclear antibodies decreased in 8 patients and the level of anti-DNA antibodies decreased in 5. Side effects included hypertension (40%), hypertrichosis (30%), gingival hypertrophy (10%), and a rise in the blood urea nitrogen level. Serum creatinine levels remained unchanged. CONCLUSION: The favorable responses observed in our patients strongly suggest that low-dose CSA can reduce the disease activity of SLE.
OBJECTIVE: To determine the effect of low-dose cyclosporin A (CSA) treatment on disease activity in systemic lupus erythematosus (SLE). METHODS: All patients in the study had active disease as defined by at least the presence of a low CH50 level. Patients were initially given 3 mg/kg/day of CSA. Dosages were adjusted individually at every visit, according to both clinical and laboratory data. RESULTS: Eleven women with SLE were enrolled in the study; 10 were evaluable. After 20 weeks of CSA treatment, the mean score for disease activity on the SLE Disease Activity Index decreased significantly, from 10.6 to 3.8 (P = 0.02). The titer of antinuclear antibodies decreased in 8 patients and the level of anti-DNA antibodies decreased in 5. Side effects included hypertension (40%), hypertrichosis (30%), gingival hypertrophy (10%), and a rise in the blood ureanitrogen level. Serum creatinine levels remained unchanged. CONCLUSION: The favorable responses observed in our patients strongly suggest that low-dose CSA can reduce the disease activity of SLE.
Authors: Xiaoyan Yang; Catherine M T Sherwin; Tian Yu; Venkata K Yellepeddi; Hermine I Brunner; Alexander A Vinks Journal: Expert Rev Clin Pharmacol Date: 2015-07-09 Impact factor: 5.045
Authors: H Ogasawara; M Sekiya; A Murashima; T Hishikawa; Y Tokano; I Sekigawa; N Iida; H Hashimoto; S Hirose Journal: Clin Rheumatol Date: 1998 Impact factor: 2.980